How can TARGIT-A have positive effects on reimbursement & guidelines?

Share this video


Andrea McKee, MD

Chairman of Radiation Oncology Department at Lahey Hospital & Medical Center, Burlington, MA, USA


Summary

Andrea McKee talks about TARGIT-A and the potential impact on reimbursement & guidelines for the treatment of breast cancer using intraoperative radiotherapy (IORT)

This recorded clinical webinar starts with a brief overview about the global guideline situation for accelerated partial breast irradiation (APBI) giving insights into different guidelines like ASTRO, ASBrS or ESTRO. Following, Andrea McKee is discussing and comparing the TARGIT-A study with the NSABP B39 trial in-depth. Finally, she is focusing on the reimbursement situation for breast cancer in the United States by presenting the RO-APM reimbursement pilot affecting IORT treatments.


To view, please login or register. MyZEISS is your gateway to all digital offerings from ZEISS.

  • Gain full access to clinical insights from peers.
  • Access the latest training and learning content for you and your team.
  • Get quick access to tools and documents. 


Share this video


Related articles